Last reviewed · How we verify
NCT05363332
Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients
trial in COVID-19 in 126 participants. Status unknown.
15 May 2023
Quick facts
| Lead sponsor | Corporacion Parc Tauli |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 126 |
| Start date | 15 November 2021 |
| Primary completion | 15 May 2023 |
| Estimated completion | 15 November 2024 |
| Sites | 3 locations across Spain |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Critical Illness — all drugs for Critical Illness →
- Hypoxemic Respiratory Failure — all drugs for Hypoxemic Respiratory Failure →
- Neurocognitive Dysfunction — all drugs for Neurocognitive Dysfunction →
Sponsor
Corporacion Parc Tauli — full company profile →
Who can join
18 and older, any sex, with COVID-19 or Critical Illness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Critically ill COVID-19 patients with acute respiratory failure, in the intensive care unit (ICU), often feature high respiratory drive, determining large inspiratory efforts resulting in high pressures and global and regional over-distention, leading to lung injury. SARS-CoV-2 neurotropic-penetration in control centers in medulla oblongata might contribute to dysregulation and to excessively high respiratory drive observed in these patients. These pathophysiological conditions may often lead to the development of patient-ventilator asynchronies in aptients under mechanical ventilation, again leading to high tidal volumes and increased lung injury. These phenomena can contribute to prolonged duration of mechanical ventilation and ICU length of stay, but also can result in long term adverse outcomes like emotional/psychological and cognitive sequelae. All them compromising the quality of life of critically ill survivors after ICU discharge. The investigators will conduct a multicenter study in adult critically ill COVID-19 patients with hypoxemic respiratory failure, aiming to: 1) characterize incidence and clustering of high respiratory drive by developing algorithms, 2) apply artificial intelligence in respiratory signals to identify potentially harmful patient-ventilator interactions, 3) characterize cognitive and emotional sequelae in critically ill COVID-19 survivors after ICU discharge and 4) identify sets of genes and transcriptomic signatures whose quantified expression predisposed to asynchronies and cognitive impairment in critically ill COVID-19 patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Flow starvation during square-flow assisted ventilation detected by supervised deep learning techniques.
de Haro C, Santos-Pulpón V, Telías I, Xifra-Porxas A, et al · · 2024 · cited 16× · PMID 38486268 · DOI 10.1186/s13054-024-04845-y -
Leveraging large language models for patient-ventilator asynchrony detection.
Suñol F, de Haro C, Santos-Pulpón V, Fernández-Gonzalo S, et al · · 2025 · PMID 40578847 · DOI 10.1136/bmjhci-2024-101426
Verify or expand the search:
- PubMed search for NCT05363332
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Corporacion Parc Tauli trials
Trials by the same sponsor.
- NCT07331805 — Conservative Management in Primary Spontaneous Pneumothorax: a Multicenter Randomized Non-inferiority Study · NA · not yet recruiting
- NCT06873360 — Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients · completed
- NCT06900335 — Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact · completed
- NCT06511700 — Implementation of the Intravitreal Injection Administered by Nurses · enrolling by invitation
- NCT07298720 — Assessing Fluid-responsiveness Using Non-invasive Hybrid Diffuse Optics on Peripheral Muscle · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05363332 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corporacion Parc Tauli
- Last refreshed: 5 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05363332.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing